Label: RETISERT- fluocinolone acetonide implant
- NDC Code(s): 24208-416-01
- Packager: Bausch & Lomb Incorporated
- Category: HUMAN PRESCRIPTION DRUG LABEL
- DEA Schedule: None
- Marketing Status: New Drug Application
Drug Label Information
Updated April 14, 2025
If you are a consumer or patient please visit this version.
- Download DRUG LABEL INFO: PDF XML
- Official Label (Printer Friendly)
-
HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use RETISERT safely and effectively. See full prescribing information for RETISERT. RETISERT (fluocinolone acetonide intravitreal ...
-
Table of ContentsTable of Contents
-
1 INDICATIONS AND USAGERETISERT - ®is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
-
2 DOSAGE AND ADMINISTRATION2.1 Dosing Information - RETISERT is implanted into the posterior segment of the affected eye through a pars plana incision. The implant contains one tablet of 0.59 mg of fluocinolone acetonide ...
-
3 DOSAGE FORMS AND STRENGTHS0.59 mg fluocinolone acetonide intravitreal implant.
-
4 CONTRAINDICATIONS4.1 Viral, Bacterial, Mycobacterial and Fungal Infections of Ocular Structures - Surgical placement of RETISERT is contraindicated in active viral diseases of the cornea and conjunctiva including ...
-
5 WARNINGS AND PRECAUTIONS5.1 Cataract Formation - Use of corticosteroids may result in posterior subcapsular cataract formation. Based on clinical trials with RETISERT, during the 3-year post-implantation period, nearly ...
-
6 ADVERSE REACTIONS6.1 Clinical Trials Experience - Ocular Events - The available safety data includes exposure to RETISERT in patients with chronic non-infectious uveitis affecting the posterior segment in two ...
-
8 USE IN SPECIFIC POPULATIONS8.1 Pregnancy - Risk Summary - Adequate and well-controlled studies with RETISERT have not been conducted in pregnant women to inform drug-associated risk. Animal reproduction studies have not ...
-
11 DESCRIPTIONRETISERT - ®(fluocinolone acetonide intravitreal implant) 0.59 mg is a sterile implant designed to release fluocinolone acetonide locally to the posterior segment of the eye at a nominal initial ...
-
12 CLINICAL PHARMACOLOGY12.1 Mechanism of Action - Corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. They inhibit the edema, fibrin deposition ...
-
13 NONCLINICAL TOXICOLOGY13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility - Long-term animal studies have not been performed to determine the carcinogenic potential or the effect on fertility of ...
-
14 CLINICAL STUDIESIn two randomized, double-masked, multicenter controlled clinical trials, 224 patients with chronic (a one year or greater history) non-infectious uveitis affecting the posterior segment of one or ...
-
16 HOW SUPPLIED/STORAGE AND HANDLINGThe implant consists of a tablet encased in a silicone elastomer cup containing a release orifice and a polyvinyl alcohol membrane positioned between the tablet and the orifice. The silicone ...
-
17 PATIENT COUNSELING INFORMATIONPatients should be advised to have ophthalmologic follow-up examinations of both eyes at appropriate intervals following implantation of RETISERT. As with any surgical procedure, there is risk ...
-
PACKAGE/LABEL PRINCIPAL DISPLAY PANELNDC24208-416-01 - Rx only - Retisert - ® (fluocinolone acetonide - intravitreal implant) 0.59 mg - STERILE - FOR INTRAVITREAL IMPLANTATION ONLY - Contents:One sterile Retisert ...
-
INGREDIENTS AND APPEARANCEProduct Information